The role of ultrasound in first-trimester screening after the introduction of NIPT as a service of public health insurance – a consensus statement of the Fetal Medicine Foundation (FMF) Germany

Die Rolle des Ersttrimester-Screenings nach Einführung von NIPT als Kassenleistung. Ein Konsensus-Statement der Fetal Medicine Foundation (FMF) Deutschland

Authors
Eberhard Merz1, Bernd Eiben2, Christian Thode3, Bernhard-Joachim Hackelöer4, Renaldo Faber5, Sevgi Tercanli6, Rudolf Alkier7

Affiliations
1 Obstetrics & Gynecology, Centre for Ultrasound and Prenatal Medicine, Frankfurt, Germany
2 Institut für Klinische Genetik Nordrhein, Labor Eiben Glaubitz, Essen, Germany
3 Laboratoriumsmedizin, MVZ wagnerstibbe für Laboratoriumsmedizin und Pathologie GmbH, Göttingen, Germany
4 Gynecology and Prenatal Medicine, Pränatale-Gynäkologie-Mammasonografie Hamburg, Praxis, Hamburg, Germany
5 Leipzig, Center of Prenatal Medicine, Leipzig, Germany
6 Praxis, Universitätsspitäl Basel, Basel, Switzerland
7 Clinical Chemistry, Labor Enders Prof Dr med Gisela Enders and Colleagues MVZ GbR, Stuttgart, Germany

Key words
Combined first-trimester screening, contingent screening, cell-free fetal DNA, prenatal ultrasound, chromosome anomalies

ABSTRACT
Combined first-trimester screening (FTS) and noninvasive prenatal testing (NIPT) have been proven to be reliable noninvasive procedures to detect the most common chromosomal abnormalities (trisomies 21, 18, 13) in the first trimester. The aim of this paper is to demonstrate the strengths and limitations of these two procedures and to give a consensus statement of the Fetal Medicine Foundation (FMF) Germany on how to use the two techniques in the first trimester after the introduction of NIPT as a service of the statutory health insurance companies in Germany.

ZUSAMMENFASSUNG
Das kombinierte Ersttrimester-Screening und der nichtinvasive DNA-Test (NIPT) haben sich als verlässliche nichtinvasive Verfahren zur Diagnostik der häufigsten Chromosomenanomalien (Trisomien 21, 18, 13) im 1. Trimenon gezeigt. Das Ziel dieser Publikation ist es, die Stärken, wie auch die Limitierungen, beider Verfahren aufzuzeigen und ein Konsensus-Statement der Fetal Medicine Foundation (FMF) Deutschland abzugeben, wie beide Techniken im 1. Trimenon eingesetzt werden sollen, nachdem NIPT als Kassenleistung in Deutschland eingeführt wurde.

Introduction
For two decades, combined first-trimester screening (FTS), including data on maternal age, ultrasound markers, and biochemical parameters, had been the most reliable noninvasive procedure to calculate the risk of chromosomal abnormalities between 11+0 and 13+6 weeks of gestation [1, 2, 3, 4, 5]. The introduction of noninvasive prenatal tests by sequencing cell-free placenta...
Merz E et al. The role of... Ultraschall in Med 2023; 44: 600–605 | © 2023. Thieme. All rights reserved.

dental DNA from maternal blood has changed the spectrum of prenatal screening rapidly due to a higher detection rate of trisomy 21, 18, 13, sex chromosomal abnormalities, and a few deletions [6, 7, 8, 9, 10]. However, chromosomal abnormalities (37.28/10,000) account for only 14.26% of the total spectrum of all malformations (261.41/10,000 including live births, stillbirths, and termination of pregnancy) (EUROCAT 2013–2019 [11]). Most of the fetal malformations are structural defects (Fig. 1) which can usually be detected by a qualified ultrasound examination.

NIPT requires only withdrawal of blood from the mother and transfer of the sample to the laboratory to gain a reliable estimation of the risk of common chromosomal anomalies without any need for an ultrasound examination. First-trimester screening, however, includes a detailed ultrasound examination that must be performed by a qualified operator.

The introduction of NIPT as a service of the statutory health insurance companies in Germany on July 1, 2022 has increased the chance to offer NIPT to pregnant women as a first-line procedure without any qualified ultrasound examination. Consequently, structural malformations and other genetic anomalies may remain undetected in the first trimester.

The aim of this paper is to compare combined FTS and NIPT, to give an overview of the advantages and limitations of the two procedures and give recommendations on how to apply both techniques in daily practice.

Strengths and limitations of FTS and NIPT

The strengths of combined first-trimester screening and NIPT, and the limitations of the two techniques are listed in ► Table 1, ► Table 2, ► Table 3, ► Table 4, ► Table 5.

Discussion

The main goal of early prenatal screening is to provide the parents-to-be with accurate information about their fetus. Undoubt-

<table>
<thead>
<tr>
<th>► Table 1</th>
<th>Advantages of combined first-trimester screening.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ultrasound allows early detection of abnormal fetal growth.</td>
<td></td>
</tr>
<tr>
<td>Ultrasound allows detection of normal and abnormal multiples.</td>
<td></td>
</tr>
<tr>
<td>Ultrasound allows early detection of many structural fetal defects [12, 13, 14, 15, 16] (see ► Table 3).</td>
<td></td>
</tr>
<tr>
<td>Ultrasound allows detection of an abnormal placental structure.</td>
<td></td>
</tr>
<tr>
<td>Transvaginal ultrasound allows good assessment of fetal anatomy in obese women.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>► Table 2</th>
<th>Limitations of combined first-trimester screening.</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-trimester screening based on MA, NT, NB, TV flow, DV flow shows a detection rate of trisomy 21 of 94.5% when using a cut-off value of 1: 500 [17].</td>
<td></td>
</tr>
<tr>
<td>First-trimester screening based on MA, NT, NB, TV flow, DV flow in combination with a detailed anomaly scan allows the detection of 95.6% of fetuses with trisomies 18 and 13, triploidy and Turner syndrome in combination with an anomaly scan [18].</td>
<td></td>
</tr>
<tr>
<td>Serum biomarkers have potential value in the detection of atypical genetic anomalies [19, 20, 21].</td>
<td></td>
</tr>
<tr>
<td>Women can be informed of the result of their risk assessment within one day.</td>
<td></td>
</tr>
<tr>
<td>Combination with early preeclampsia screening [22, 23].</td>
<td></td>
</tr>
<tr>
<td>The number of invasive procedures can be reduced.</td>
<td></td>
</tr>
<tr>
<td>Detection of a structural fetal defect enables targeted invasive procedures and further genetic analysis if necessary.</td>
<td></td>
</tr>
<tr>
<td>MA = maternal age, NT = fetal nuchal translucency, NB = nasal bone, TV = tricuspid valve, DV = Ductus venosus</td>
<td></td>
</tr>
</tbody>
</table>

Edy, cell-free fetal DNA screening in maternal blood (NIPT) is currently the best noninvasive screening test for assessing the risk of trisomies 21, 18, 13 and sex chromosomal abnormalities [26], and it also has some value in assessing the risk of 22q11.2 deletion syndrome [28, 29]. However, NIPT is still an advanced screening test and not a diagnostic test. It may be limited by its moderate to low positive predictive value, especially for conditions with low prevalence in the tested population. Furthermore, the test has several limitations (see ► Table 5) and requires qualified genetic
The implementation of NIPT in public-health-based programs allows two different application models: 1. NIPT as a first-line counseling prior to the test and after the test result is available (German Gene Diagnostics Act [37]). The number of invasive procedures can be reduced.

counseling prior to the test and after the test result is available (German Gene Diagnostics Act [37]).

The implementation of NIPT in public-health-based programs allows two different application models: 1. NIPT as a first-line screening tool (effectively replacing conventional serum and NT screening) [38, 39] or 2. NIPT as a second screening step (contingent screening model) in the case of an abnormal FTS result [38, 40]. The advantages of NIPT for first-line screening are the simplicity of the procedure and the fact that there is no need for specialized training besides qualifications in prenatal counseling.

NIPT is limited to singleton and twin pregnancies. NIPT is contraindicated in higher degree multiples.

The time until the result is available is longer than with first-trimester screening. Low fetal cfDNA fraction <4% in maternal blood is seen in about 2–5% of the cases [34] and results with low fetal fractions are of limited value or fail to provide a result after one blood drawing. In obese pregnant women the risk of a low fetal cfDNA fraction in maternal blood is increased [35]. In pregnancies with failed cfDNA test, fetal chromosomal abnormalities are over-represented [34, 36].

Table 5 Limitations of NIPT.

NIPT is an advanced screening test for trisomies 21, 18, and 13 and sex chromosome aberrations [31, 32], but has currently no value in the detection of many other chromosomal abnormalities.

NIPT has limited value in the detection of deletions [28, 29]. NIPT may produce false-positive results: trisomy 21 (0.04%), trisomy 18 (0.04%), trisomy 13 (0.04%) and sex chromosome aneuploidies (SCA) (monosomy X 0.14%, SCA other than monosomy X (0.004%) [26], and false-negative results [33].

NIPT does not allow the detection of structural defects of the fetus. NIPT is limited to singleton and twin pregnancies.

NIPT is contraindicated in higher degree multiples.

NIPT is contraindicated in vanishing twin.

Table 3 Structural fetal defects detectable and not detectable with 3D ultrasound in the first trimester [25].

<table>
<thead>
<tr>
<th>Structural defects detectable with 3D ultrasound in the first trimester</th>
<th>Structural defects not detectable with 3D ultrasound in the first trimester</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yolk sac abnormalities</td>
<td>Microcephaly</td>
</tr>
<tr>
<td>Umbilical cysts</td>
<td>Macrocephaly</td>
</tr>
<tr>
<td>Exencephaly/anecephaly</td>
<td>Ventriculomegaly</td>
</tr>
<tr>
<td>Encephalocele</td>
<td>Agenesis of corpus callosum</td>
</tr>
<tr>
<td>Holoprosencephaly</td>
<td>Subtle cardiac defects</td>
</tr>
<tr>
<td>Facial clefts/absent nasal bone/ retrognathia</td>
<td>Lung abnormalities</td>
</tr>
<tr>
<td>Low set ears</td>
<td>Bowel obstruction</td>
</tr>
<tr>
<td>Spina bifida</td>
<td>Hydrodromphosis</td>
</tr>
<tr>
<td>Severe cardiac defects</td>
<td>Bladder extrophy</td>
</tr>
<tr>
<td>Abdominal wall defects</td>
<td>Achondroplasia</td>
</tr>
<tr>
<td>Hydrops</td>
<td>Pena-Shokeir syndrome</td>
</tr>
<tr>
<td>Megacystis</td>
<td></td>
</tr>
<tr>
<td>Achondrogenesis</td>
<td></td>
</tr>
<tr>
<td>Limb defects, polydactyly</td>
<td></td>
</tr>
<tr>
<td>Body stalk anomaly</td>
<td></td>
</tr>
<tr>
<td>Kartagener syndrome</td>
<td></td>
</tr>
<tr>
<td>Severe amniotic band syndrome</td>
<td></td>
</tr>
<tr>
<td>Conjoined twins</td>
<td></td>
</tr>
<tr>
<td>Single umbilical artery</td>
<td></td>
</tr>
</tbody>
</table>

Despite these limitations, NIPT has been shown to improve the diagnostic performance of ultrasound screening for many structural malformations, early fetal growth restriction, twin abnormalities, or abnormal placental structure. In contrast, qualified combined first-trimester screening with a detailed ultrasound ex-
amination allows the detection of the most common trisomies, triploidy, and the demonstration or exclusion of various structural defects (▶ Table 3). As early prenatal screening provides more than just risk assessment of trisomies 21, 18 and 13, every pregnant woman should receive comprehensive information about current noninvasive and invasive procedures and early pre-eclampsia screening [22, 23, 46, 47].

There is broad consensus in several ultrasound societies and publications that a detailed first-trimester ultrasound examination should always be performed prior to an NIPT procedure [40, 47, 48, 49, 50, 51, 52]. Since NIPT has been covered by statutory health insurance since July 1, 2022, NIPT will become more popular and FTS biochemical screening, which is subject to a fee, will continue to decline. The hormone parameters free β-HCG and PAPP-A will no longer have the importance they had in pre-NIPT times, but they may continue to be offered as an option, or in situations where NIPT is not recommended (e.g., vanishing twin) or in cases with very low fetal DNA fractions. On the other hand, PAPP-A is a biomarker that is also used in pre-eclampsia screening in the first trimester [23].

As a result, FMF Germany recommends performing NIPT as a contingent procedure, either once the FTS results are available (▶ Fig. 3) or directly after the FTS ultrasound examination has shown no structural fetal malformation and normal NT (▶ Fig. 4).

**Conclusion**

While NIPT is currently focusing on screening for trisomy 21, 18, 13 and sex chromosomal abnormalities only, combined first-trimester screening with a detailed ultrasound check of the fetal anatomy is of major importance for the early detection of structural defects. Consequently, NIPT should not replace combined first-trimester screening with a detailed check of the fetal morphology. Therefore, the optimal first-trimester screening approach would be to first perform a detailed ultrasound examination and a risk calculation with the basic parameters of maternal age, crown-rump length, and nuchal translucency thickness, and – for experienced operators – with the additional ultrasound parameters absence/ presence of nasal bone, ductus venosus flow, and tricuspid regurgitation. If no structural abnormality is found and the risk assessment shows a result in the low-risk or intermediate-risk group, NIPT can be performed for advanced screening for trisomies 21, 18, 13 and sex chromosome aneuploidies. If a structural abnormality is detected during the ultrasound examination, NIPT is no longer advisable and instead, CVS or an amniocentesis should be performed for karyotyping (▶ Fig. 3).
as well as microarray [53] and genome sequencing [54, 55] if required.

Finally, the key statements for early prenatal screening are listed in Table 6.

Conflict of Interest

The authors declare that they have no conflict of interest.

References


